11:15 AM EST - BriaCell Therapeutics Corp. : Announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors, outperforming ADC drugs in hormone receptor positive metastatic breast cancer patients. BriaCell Therapeutics Corp.
shares T.BCT are trading up $0.36 at $5.69.
